Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
A Phase 2, Open-Label, Non-Comparative Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) as First-Line Therapy in the Treatment of Invasive Aspergillosis
Sponsor: Astellas Pharma Inc
Terminated
Inadequate enrollment
Other terminated trials from Astellas Pharma Inc
- Primary Mitochondrial Myopathy · Phase PHASE2 · May 2024
- Prostate Cancer · Jan 2024
- Anemia · Phase PHASE3 · Jun 2023
- Metastatic Castration Resistant Prostate Cancer · Phase PHASE1/PHASE2 · Nov 2022
- Breast Cancer · Phase PHASE2 · Sep 2022
More terminations from Astellas Pharma Inc
A PHASE2 clinical study on Aspergillosis, this trial is terminated or withdrawn. The trial is conducted by Astellas Pharma Inc and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .